Express Mail No. EV335855683US

ATTY. DOCKET NO.	APPLICATION NO.
9516-0048-999	10/032,286
APPLICANT	
Robarge *et al.*	
FILING DATE	GROUP
December 21, 2001	1625

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CC	AA	3,992,189	11/16/76	Goddard			
	AB	5,045,108	9/3/91	Elbe et al.			
	AC	5,198.402	3/30/93	Kaji et al.			
	AD	5,326,800	7/5/94	Horn et al.			
	AE	5,385,901	1/31/95	Kaplan et al.			
	AF	5,605,914	2/25/97	Muller			
	AG	5,635,517	6/3/97	Muller et al.			
	AH	5,658,940	8/19/97	Muller et al.			
	AI	5,698,579	12/16/97	Muller			
	AJ	5,703,098	12/30/97	Muller et al.			
	AK	5,728,845	3/17/98	Muller et al.			
	AL	5,736,570	4/7/98	Muller et al.			
	AM	5,798,368	8/25/98	Muller et al.			
	AN	5,801,195	9/1/98	Muller et al.			
	AO	5,874,448	2/23/99	Muller et al.			
	AP	5,877,200	3/2/99	Muller			
	AQ	5,929,117	7/27/99	Muller et al.			
	AR	5,955,476	9/21/99	Muller et al.			
	AS	5,968,945	10/19/99	Muller et al.			
	AT	6,011,050	1/4/00	Muller et al.			
	AU	6,020,358	2/1/00	Muller et al.			
	AV	6,046,221	4/4/00	Muller et al.			
	AW	6,075,041	6/13/00	Muller			
	AX	6,130,226	10/10/00	Muller et al.			
	AY	6,180,644	1/30/01	Muller et al.			
	AZ	6,200,987	3/13/01	Muller			
CC	BA	6,214,857	4/10/01	Muller et al.			

CC 4/15/04

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	BB	EP 0 797 437	10/1/97	Europe				
	BC	EP 1 004 572	5/31/00	Europe				
	BD	EP 1 004 580	5/31/00	Europe				
	BE	EP 1 004 581	5/31/00	Europe				
	BF	WO 00/25777	5/11/00	PCT				
	BG	WO 00/38521	7/6/00	PCT				
	BH	WO 00/55134	9/21/00	PCT				
	BI	WO 92/18496	10/29/92	PCT				
	BJ	WO 95/01348	1/12/95	PCT				
	BK	WO 96/20705	7/11/96	PCT				
	BL	WO 96/20926	7/11/96	PCT				
	BM	WO 97/08143	3/6/97	PCT				
	BN	WO 97/12859	4/10/97	PCT				
	BO	WO 97/23457	7/3/97	PCT				
	BP	WO 97/37988	10/16/97	PCT				
	BQ	WO 98/03502	1/29/98	PCT				
	BR	WO 98/06692	2/19/98	PCT				
	BS	WO 98/24763	6/11/98	PCT				
	BT	WO 98/41525	9/24/98	PCT				
	BU	WO 98/54170	12/3/98	PCT				
	BV	WO 99/06041	2/11/99	PCT				
	BW	WO 99/46258	9/16/99	PCT				
	BX	WO 99/47512	9/23/99	PCT				

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	BY	Corral et al., 1999, "Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α", J Immunol.163:380-386
	BZ	He et al., 1993, "Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease", Abstracts of Papers, 206th ACS National Meeting, Abstract No. 216
	CA	Muller et al., 1996, "Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity", J. Med. Chem. 39:3238-3240
	CB	Muller et al., 1998, "Thalidomide analogs and PDE4 inhibition" Bioorg. Med. Chem. Lett. 8:2669-2674
	CC	Muller et al., 1999, "Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production", Bioorg. Med. Chem. Lett. 9:1625-1630

EXAMINER CL **DATE CONSIDERED** 1/15/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 9516-0048-999	APPLICATION NO 10/032,286
	APPLICANT Robarge *et al.*	
	FILING DATE December 21, 2001	GROUP 1625

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CD	3,992,189	11/16/76	Goddard			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	CE	WO 97/45117	12/4/97	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	CF	Bundgaard, "Design of prodrugs" Elsevier, Amsterdam - New York - Oxford, p.27-43 (1986).
	CG	Corral et al., 1996, "Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity" Mol. Med. Jul;2(4):506-15
	CH	Database CAPLUS on STN (Columbus, OH, USA), No. 118:131893, 'The hydrolysis of azidoprofen esters: a model for a soft anti-inflammatory drug for topical application' Int. J. Phar. Vol. 89, p. 65-74 (1993), abstract.
	CI	Database CAPLUS on STN (Columbus, OH, USA), No. 128:140615, 'Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and 1-oxoisoindolines and method of reducing TNF-alpha levels' WO98/03502, abstract and registry no. 191732-76-0, 202271-87-2, 202271-88-3, 202271-89-4, 202271-90-7.
	CJ	Database CAPLUS on STN (Columbus, OH, USA), No. 130:38290, 'Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and 1-oxoisoindolines and method of reducing TNF-alpha levels' WO98/54170, abstract and registry no. 202271-88-3, 216669-27-1; 191732-72-6.
	CK	Database CAPLUS on STN (Columbus, OH, USA), No. 131:214197, 'Preparation of 2-(2,6-dioxo3-fluoropiperidin-3-yl) isoindolines for reducing inflammatory cytokine levels' US 5,955,476, abstract and registry no. 220460-56-0, 220460-57-1, 220460-62-8, 220460-64-0.
	CL	Marriott et al., 2001, "Immunotherapeutic and antitumor potential of thalidomide analogue" Expert Opin. Biol. Ther. Jul;1(4):675-82. Review
	CM	Miyachi et al. 1998, "Tumor necrosis factor-alpha production enhancing activity of substituted 3'-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity" Chem. Pharm. Bull. (Tokyo). Jul;46(7):1165-8.
	CN	Price et al., 2002, "5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis" Ther. Drug monit. Feb;24(1):104-10.

EXAMINER	DATE CONSIDERED 1/15/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.